Back to top
more

TransMedics Group (TMDX)

(Delayed Data from NSDQ)

$85.50 USD

85.50
1,143,210

-0.85 (-0.98%)

Updated Nov 7, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks.com featured highlights include TransMedics, Iamgold, Graham and GIII Apparel

by Zacks Equity Research

TransMedics, Iamgold, Graham and GIII Apparel have been highlighted in this Screen of The Week article.

KIDS Stock Gains From Its New Enabling Technologies Division Launch

by Zacks Equity Research

OrthoPediatrics recently launched its Enabling Technologies division, set to generate sustainable revenue growth and gain access to new markets and specialties beyond orthopedics.

Santanu Roy headshot

4 Stocks Backed by High Efficiency for Solid Gains Amid Volatility

by Santanu Roy

Invest in stocks of TMDX, IAG, GHM and GIII to tap their high-efficiency levels.

CVS Stock Gains From Its Birth Control Prescribing Service Launch

by Zacks Equity Research

CVS Health announces that nearly 400 CVS Pharmacy locations in Massachusetts have started offering hormonal contraceptive prescribing services.

Labcorp Stock Gains From Market Expansion Efforts Amid Macro Woes

by Zacks Equity Research

LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.

Sanara Stock Gains From New US Distribution Deal With ChemoMouthPiece

by Zacks Equity Research

SMTI, along with InfuSystem, inked a U.S. distribution agreement with ChemoMouthpiece. Under the agreement, ChemoMouthpiece's oral cryotherapy device will be distributed in cancer centers.

Should You Continue to Retain OMCL Stock in Your Portfolio Now?

by Zacks Equity Research

Omnicell is well-placed for growth in the upcoming quarters owing to its progress in achieving the Autonomous Pharmacy goal.

Paragon 28 Stock Gains From the Latest Launch of Its Right-Angle Drill

by Zacks Equity Research

FNA launched the Right-Angle Drill to enhance the APEX 3D Total Ankle Replacement System. The drill is designed to improve tibia preparation.

Reasons to Retain ResMed Stock in Your Portfolio for Now

by Zacks Equity Research

Strong demand for RMD's market-leading mask portfolio raises investors' optimism.

Will Trinity Biotech Stock Gain From Its Latest Patent Process?

by Zacks Equity Research

TRIB announces updates on its European patented process. The company aims to use this process to improve the functionality of its glucose biosensor in its next-gen CGM technology.

PBH Stock Might Get a Boost From Focused Brand-Building Efforts

by Zacks Equity Research

Prestige Consumer puts emphasis on brand building and product innovation in niche consumer healthcare categories to improve the lives of its consumers.

Can HITI Stock Get a Boost From Bricks-and-Mortar Sales in Q3 Earnings?

by Zacks Equity Research

Given High Tide's progress in executing its strategic initiatives, we expect it to report robust Q3 bricks-and-mortar segment sales.

Will Paragon 28 Stock Gain From the Latest Product Launch of R3FLEX?

by Zacks Equity Research

FNA recently introduced the R3FLEX Stabilization System, whose design should allow surgeons to restore a patient's soft tissue to a more natural anatomy.

Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now

by Zacks Equity Research

Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.

Align Technology Stock Dips on Macroeconomic Issues, FX Headwind

by Zacks Equity Research

ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This is resulting in a decline in the company's revenues.

Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?

by Zacks Equity Research

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.

QIAGEN Stock Likely to Gain on Collaboration for APOE Genotyping

by Zacks Equity Research

QGEN collaborates with Eli Lilly to develop a QIAstat-Dx IVD panel for APOE genotyping.

Should You Continue to Retain ABT Stock in Your Portfolio Now?

by Zacks Equity Research

Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.

New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues

by Zacks Equity Research

MYGN focuses on effective capital deployment in key areas, including new tech-enabled tools and capabilities, innovation and commercial capabilities.

Reasons to Retain STERIS Stock in Your Portfolio for Now

by Zacks Equity Research

STE's strong prospects in the healthcare business arm bode well for investors.

Zynex Stock Rises on FDA Clearance of Its New Pain Management Device

by Zacks Equity Research

ZYXI recently received the Food and Drug Administration clearance for its new TensWave device. TensWave is designed to provide a comprehensive pain management solution.

Should You Consider Retaining ZBH Stock in Your Portfolio Now?

by Zacks Equity Research

Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.

Should You Continue to Retain PODD Stock in Your Portfolio Now?

by Zacks Equity Research

Insulet's Omnipod 5 is set to drive growth in the upcoming quarters. Meanwhile, the stock is facing challenges due to economic uncertainties.

Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock

by Zacks Equity Research

Valneva and Pfizer report positive immunogenicity and safety data from their Phase 2 study of the VLA15 vaccine. Phase 3 trials for VLA15 are in progress.

Reasons to Hold Tandem Diabetes Stock in Your Portfolio Now

by Zacks Equity Research

Innovations and a robust diabetes market outlook raise investors' optimism for TNDM.